SCHEMBL4772658

SCHEMBL4772658

NC(C=O)C(c1ccccc1C(F)(F)F)N1CCN(C(=O)c2cc(F)ccc2C(F)(F)F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 1/20 0.39
CACNA1B Q00975 1/20 0.39
CACNB1 Q02641 1/20 0.39
CACNA1C Q13936 1/20 0.39
EPHX2 P34913 1/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
SCD O00767 3/20 0.39
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
SCN5A Q14524 1/20 0.38
SCN9A Q15858 1/20 0.38
P2RX7 Q99572 5/20 0.37
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTR2B P41595 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775889 0.92 SCN5A (0.42) EPHX2HCRTR1HCRTR2SCDPSEN1
SCHEMBL4774662 0.84 CACNA1B (0.41) CACNA2D1CACNA1BCACNB1CACNA1CHCRTR1
SCHEMBL4753765 0.82 HCRTR1 (0.44) HCRTR1HCRTR2SCDPSEN1PSEN2
SCHEMBL4837579 0.81 SCD (0.38) EPHX2HCRTR1HCRTR2SCDSCN5A
Hydrochloric Acid SCHEMBL3466376 0.81 HCRTR1 (0.43) HCRTR1HCRTR2SCDPSEN1PSEN2
SCHEMBL4776901 0.80 L3MBTL1 (0.51) CACNA2D1CACNA1BCACNB1CACNA1CEPHX2
SCHEMBL4778523 0.78 SCD (0.40) CACNA2D1CACNA1BCACNB1CACNA1CSCD
SCHEMBL4753470 0.74 SCD (0.51) SCDP2RX7CYP2C9CYP2C19HTR2B
SCHEMBL4780056 0.74 SCD (0.38) SCD
SCHEMBL4773443 0.74 HDAC8 (0.42) HCRTR1HCRTR2SCDPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed